The U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application (ANDA) numbered 076346 submitted by Teva Pharmaceuticals USA, Inc. for the loop diuretic torsemide.
The approved product is an oral tablet marketed under the brand name TORSEMIDE, available in four strengths – 5 mg, 10 mg, 20 mg, and 100 mg – each designated as prescription‑only.
The submission history includes an original filing on 30 May 2003, subsequent manufacturing (CMC) and labeling supplements, with the most recent labeling supplement submitted on 4 May 2020.
FDA labeling classifies torsemide as a loop diuretic that increases diuresis at the loop of Henle.
Regulatory UpdatesAug 26, 2026•1 min read
FDA Approves Teva Torsemide Generic Tablets (ANDA 076346)
The FDA has approved Teva Pharmaceuticals’ ANDA 076346 for torsemide oral tablets in 5 mg, 10 mg, 20 mg and 100 mg strengths, prescription‑only.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating